Abivax: Phase 3 Data Was A Home Run, Top Target For M&A In 2026
Source: SeekingAlpha
2025-11-08 07:57:19 ET
Obefazimod's ABTECT Phase 3 Induction Data Materially Beat Expectations
I initiated Abivax ( ABVX ) with a buy rating in July 2025. My thesis revolved around the positive phase 3 data readout. As my readers recall, my view was that if placebo-adjusted clinical remission came above 10%, it would be a win and move the stock multiple times....
Read the full article on Seeking Alpha
For further details see:
Abivax: Phase 3 Data Was A Home Run, Top Target For M&A In 2026
Abivax
NASDAQ: AAVXF
AAVXF Trading
0.8% G/L:
$125.656 Last:
700 Volume:
$124.66 Open:
